Development of a Product to Prevent Binding of SARS-COV-2 within the Respiratory Airway and Cardiovascular System

The SARS beta coronaviruses, SARS-CoV, which caused the SARS (Severe Acute Respiratory Syndrome) outbreak in 2003 and the new SARS-CoV-2, which causes COVID-19, bind to angiotensin converting enzyme 2 (ACE2) receptors in the lower respiratory tracts of infected patients to gain entry into the lungs. Viral pneumonia and potentially fatal respiratory failure may result in susceptible persons after 10-14 days. Our proposed product will bind to SARS-COV-2 and reduce the opportunity for it to enter the body.